1,498 research outputs found
Response from Drs. Formica/Zaniboni to Dr. Milano
No full textWe would like to thank Dr. Milano et al. for the point
they made on the possible role of drug-induced immune
response occurring during treatment with either anti-VEGF
or anti-EGFR agent
The 'death pace' in the CO.17 trial
No full textIn an era where the cost of care in oncology is rising, suggestions of new frameworks that may help in orienting biomarker discovery are highly desirable. We propose a different perspective for looking at survival data, which we call 'death pace' analysis, which focuses on the variation of the gap between survival curves over time and that may make it easier to identify subpopulations with distinct predictive molecular features. The recently published data on EJC on the impact of the primary colonic site in the CO.17 trial seem to be particularly suitable for the death pace analysis
The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside
No full textSince 2013, informative trials exploring the optimal use of available biologic agents in the first-line setting of metastatic colorectal cancer (mCRC) have been presented. These trials have opened a stimulating debate on the biological effect that first-line therapies may have on subsequent lines of treatment even long after the first-line progression.We reviewed available preclinical and clinical data on the effect of different sequences of the biological drugs approved for use in mCRC patients. The importance of molecular selection of patients based on RAS mutational status and toxicity and quality-of-life issues were also analyzed.Convincing evidence exists on the optimal therapeutic effect obtained by using anti-EGFR agents in first-line treatment before anti-VEGF agents. On the contrary, up-front anti-VEGF agents' use seems to determine biological changes that increase the risk of acquired resistance to subsequent EGFR inhibitors. This hypothesis is confirmed by the scarce evidence of EGFR inhibitor activity in second-line treatment. Such a therapeutic optimum is subject to a fine molecular selection based on RAS mutational status.There is accumulating evidence suggesting that, after precise and well-established molecular selection, anti-EGFR agents deliver their maximum efficacy in mCRC patients when given early in the treatment strategy. Their toxicity profile seems manageable under the supervision of experienced physicians. Large randomized trials prospectively confirming the impact of different sequencing strategies are eagerly awaited
Targeted therapy in first line treatment of RAS wild type colorectal cancer
No full textThe debate on the optimal drug combination for treating chemotherapy-naïve patients with metastatic colorectal cancer has recently become particularly heated. The present editorial will review recent data on this topic. The FIRE-3 and PEAK trials have shown a 7.5 to 12 mo survival advantage with the use anti-epidermal growth factor receptor (anti-EGFR) antibodies. The CALGB 80405 has shown no difference between anti-EGFR and anti-vascular endothelial growth factor agents. All three trials have consistently shown a significant increase in objective response rate. These data suggest that there is a subset of metastatic colorectal cancer patients, rigorously selected by molecular profiling, who particularly benefit from an anti-EGFR-based regimen in the first-line setting
Formica aethiops
No full text26. Formica aethiops. B.M. Formica aethiops, Latr. Hist. Nat. Fourm. 101 [[male]] [[queen]] [[worker]], pl. 2. f. 4. A. B. [[worker]]. Formica aethiops, Losana, Form. Piem. Mem. Accad. Torino, xxxvii. 312. St. Farg. Hym. i. 212. 13. Mayr. Form. Austr. 41. 4; Ungar. Ameis. 5. 3. Nyl. Form. Fr. et d'Alger. Ann. Sc. Nat. v. 54. 2 (1856). Formica nigrata, Nyl. Addit. Adno. Mon. Form. 35? Hab. France; Germany; Helsingfors.Published as part of Smith, F., 1858, Catalogue of the hymenopterous insects in the collection of the British Museum. Part VI. Formicidae., London :British Museum on pages 9-1
Formica micans
No full text100. Formica micans. Formica micans, Nyl. Fourm. Fr. et d'Alg. Ann. Sc. Nat. v. 55,4 [[worker]]. Hab. Algeria.Published as part of Smith, F., 1858, Catalogue of the hymenopterous insects in the collection of the British Museum. Part VI. Formicidae., London :British Museum on page 3
Formica opaca
No full text32. Formica opaca. B.M. Formica opaca, Nyl. Form. Fr. et d'Alg. Ann. Sc. Nat. v. 55. 3. (1856) [[worker]]. Savign. Egypt, x. 20. f. 7 [[worker]]. Hab. France; Algeria.Published as part of Smith, F., 1858, Catalogue of the hymenopterous insects in the collection of the British Museum. Part VI. Formicidae., London :British Museum on page 1
Formica procidua
No full text137. Formica procidua. Formica procidua, Erichs. Wiegm. Arch. (1842) v. 230, 259. Hab. Tasmania.Published as part of Smith, F., 1858, Catalogue of the hymenopterous insects in the collection of the British Museum. Part VI. Formicidae., London :British Museum on page 4
Role of systemic inflammation and CD45RO+CD8+ cells in metastatic colorectal cancer = Ruolo dell’infiammazione e delle cellule CD45RO+CD8+ nei tumori colorettali metastatici
No full textBACKGROUND: Systemic inflammation as measured by the inflammatory index Neutrophil/lymphocyte ratio(N/L) and activation of innate immunity pathways driven by TLR4 are negative prognostic factors for patients with localized colorectal cancer (CRC). Moreover, adaptive immunity pathways driven by CD45RO and PD-1 have proven pivotal in regulating antitumor response and correlate with survival for localized CRC. In the present study we evaluated if N/L and CD45RO, PD-1, and TLR4 peripheral expression was associated with outcome in metastatic CRC (mCRC) treated with standard first-line chemotherapy including bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B).
PATIENTS AND METHODS: mCRC patients eligible for this prospective study (clinicaltrial.gov NCT01533740) were treated with first-line FOLFIRI-B. Blood was drawn before the first and third cycle and analyzed by flow cytometry for frequency (%) of CD4+, CD8+, CD45RO+, and PD1+ mononuclear cells and for TLR4 expression on neutrophils. N/L was assessed before each treatment cycle. Innate and adaptive immune variables were correlated with outcome by Cox regression analysis, together with common clinical,biochemical and histological variables.
RESULTS:
Among 403 consecutive patients referred to our Unit between June 2008 and October 2011, 106 patients, 43 female and 63 male, were eligible for this trial and assessed for N/L; 31 patients had samples available for CD45RO, PD-1, and TLR4 expression analysis. At multivariate Cox regression analysis of all 106 enrolled patients, only N/L and CRP were confirmed to be independent prognostic factors, with N/L being the most powerful prognosticator (exp(b)=1.80,p 0.0019;mOS for patients with N/L< and >3.5= 41 v 12 months, respectively,p 0.01).Surprisingly, N/L changes during chemotherapy among patients with stable disease had an opposite effect on survival: patients with increasing or stable N/L had a 67% reduction in the risk of death as compared with patients with significant N/L decrease,p 0.02. Among the 31 patients assessable for adoptive immune variables, two cycles of chemotherapy determined changes that were
prognostically meaningful. Pre-third-cycle (ptc) CD45RO+CD8+cell% displayed a statistically significant association with progression-free survival (PFS) (median PFS 22.4 vs. 9.4 months for patients with CD45RO+CD8+cell%> vs
Formica fuscipes
No full text35. Formica fuscipes, Formica fuscipes, Mayr. Form. Austr. 45. 6 [[worker]]. Nyl. Form. Fr. et d'Alger. Ann. Sc. Nat. v- 57. 9 (1856). Hab. Austria; Italy; France.Published as part of Smith, F., 1858, Catalogue of the hymenopterous insects in the collection of the British Museum. Part VI. Formicidae., London :British Museum on page 1
- …
